N/A
N=98
Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation
Prostate Cancer Prevention
Bottom Line
View on ClinicalTrials.gov: NCT01265953 ↗Enrolled (actual)
98
Serious AEs
0.0%
Results posted
Jul 2017
Primary outcome: Primary: Change of Total Urine SFN (Sulforaphane) Metabolites — 4.75; -0.02 micromolar (µM) concentrations of urina
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- SFN-rich broccoli sprout extract capsules (Drug); Gelatin capsule containing microcrystalline cellulose. (Dietary_supplement)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- Male
- Sponsor
- Portland VA Medical Center
- Primary completion
- Oct 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change of Total Urine SFN (Sulforaphane) Metabolites |
4.75; -0.02 | — |
| PRIMARY Change of Total Plasma SFN (Sulforaphane) Metabolites Level |
0.12; -0.0003 | — |
| PRIMARY Percentage of Ki67 Positive Cells up to 8 Weeks Post-randomization |
1.8; 1.9 | — |
| PRIMARY Expression of Histone Deacetylase 6 (HDAC6) |
187; 183 | — |
Summary
The objective of the study is to identify mechanisms by which compounds found in cruciferous vegetables alter gene expression via epigenetic modifications (changes in gene expression) and may prevent prostate cancer development.
The investigators have found that sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables, inhibits histone deacetylase (HDAC) activity in human colorectal and prostate cancer cells.
Eligibility Criteria
Inclusion Criteria
- Men scheduled for a prostate biopsy
- Age 21 years or older
- Signed informed subject consent
Exclusion Criteria
- Definitive diagnosis with prostate cancer
- Significant active medical illness which in the opinion of the investigator or clinician would preclude protocol treatment
- Diagnosis of liver disease as noted on the patient problem list or baseline total bilirubin greater than institutional upper limit of normal
- Subject reported allergy or sensitivity to cruciferous vegetables
- Use of oral antibiotics, with the exception of doxycycline, within three months prior to randomization
- Use of warfarin or need for therapeutic anticoagulation at time of biopsy or at anytime during the course of the trial.
- Current oral steroid therapy
- Current therapy with valproate or other pharmacological drugs associated with HDAC inhibition
- Diagnosed dementia as noted on the patient problem list or other significant mental illness that may impact the subjects' ability to follow instructions or comply with the study protocol
- Patient may not be a part of another flagged study
- Patients already taking SFN dietary supplements
Data sourced from ClinicalTrials.gov (NCT01265953). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.